A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs.
We recently constructed a novel non-replicating dominant-negative HSV-2 recombinant viral vaccine (CJ2-gD2) capable of expressing various HSV-2 antigens that are dominant targets of HSV-2-specific CD8 T-cell response. Importantly, CJ2-gD2 expresses gD2, the HSV-2 major antigen glycoprotein D, as eff...
Main Authors: | Pengwei Zhang, Lining Xie, John W Balliet, Danilo R Casimiro, Feng Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4076306?pdf=render |
Similar Items
-
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
by: Peter B Gilbert, et al.
Published: (2017-01-01) -
Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.
by: Joshua J Geltz, et al.
Published: (2015-01-01) -
Efficacy of the anti-VZV (anti-HSV3) vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study
by: Le Goaster J, et al.
Published: (2012-07-01) -
The epidemiology and natural history of genital herpes simplex virus (HSV) infection
by: Ramaswamy, Meghna
Published: (2006) -
Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral Gene Encoding Glycoprotein B
by: Amanda M. Casto, et al.
Published: (2020-08-01)